Mesa Laboratories (NASDAQ:MLAB) SVP Sells $116,561.77 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) SVP Brian David Archbold sold 1,151 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $101.27, for a total value of $116,561.77. Following the completion of the sale, the senior vice president directly owned 3,710 shares of the company’s stock, valued at approximately $375,711.70. This represents a 23.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mesa Laboratories Stock Performance

Shares of MLAB stock opened at $95.10 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. Mesa Laboratories, Inc. has a 1-year low of $55.45 and a 1-year high of $113.99. The stock has a market capitalization of $525.43 million, a PE ratio of 79.25 and a beta of 0.94. The business has a 50-day moving average of $101.94 and a 200 day moving average of $90.77.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by ($0.25). The business had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same period in the previous year, the business earned ($1.31) earnings per share.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Friday, May 29th were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, May 29th. Mesa Laboratories’s dividend payout ratio (DPR) is 53.33%.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Mesa Laboratories currently has an average rating of “Reduce” and a consensus target price of $94.00.

Institutional Investors Weigh In On Mesa Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the stock. Simcoe Capital Management LLC purchased a new stake in shares of Mesa Laboratories during the 3rd quarter valued at about $12,794,000. Boston Partners increased its stake in Mesa Laboratories by 2,009.5% in the third quarter. Boston Partners now owns 114,357 shares of the medical instruments supplier’s stock worth $7,664,000 after purchasing an additional 108,936 shares during the period. Roubaix Capital LLC bought a new stake in Mesa Laboratories during the 3rd quarter valued at about $5,137,000. Millennium Management LLC raised its stake in shares of Mesa Laboratories by 131.9% during the third quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier’s stock valued at $8,967,000 after acquiring an additional 76,107 shares in the last quarter. Finally, Mason Capital Management LLC bought a new stake in Mesa Laboratories during the 3rd quarter valued at $4,711,000. Institutional investors own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.